Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

CVS Earnings Downturn Attributable To Pharmacist Shortage, CEO Ryan Says

  • News

Executive Summary

CVS' downturn in expected earnings for 2001 is attributable to the pharmacist shortage, CEO Tom Ryan told a conference call June 27.

You may also be interested in...



CVS Says Lack Of New Drug Launches Is One Reason For Earnings Decline

The slowdown in new drug approvals is among the factors contributing to a downturn in CVS' earnings, CEO Tom Ryan told a conference call Oct. 30

CVS Says Lack Of New Drug Launches Is One Reason For Earnings Decline

The slowdown in new drug approvals is among the factors contributing to a downturn in CVS' earnings, CEO Tom Ryan told a conference call Oct. 30

CVS Pharmacy Incentive Program Targets Lost Customers

CVS is beginning an incentive program to try to win back pharmacy customers who have stopped using CVS stores to fill prescriptions.

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS038109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By